Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Malissa Richmond"'
Autor:
Emily Grist, Stefanie Friedrich, Christopher Brawley, Larissa Mendes, Marina Parry, Adnan Ali, Aine Haran, Alex Hoyle, Claire Gilson, Sharanpreet Lall, Leila Zakka, Carla Bautista, Alex Landless, Karolina Nowakowska, Anna Wingate, Daniel Wetterskog, A. M. Mahedi Hasan, Nafisah B. Akato, Malissa Richmond, Sofeya Ishaq, Nik Matthews, Anis A. Hamid, Christopher J. Sweeney, Matthew R. Sydes, Daniel M. Berney, Stefano Lise, STAMPEDE investigators, Mahesh K. B. Parmar, Noel W. Clarke, Nicholas D. James, Paolo Cremaschi, Louise C. Brown, Gerhardt Attard
Publikováno v:
Genome Medicine, Vol 14, Iss 1, Pp 1-15 (2022)
Abstract Background Genomic copy number alterations commonly occur in prostate cancer and are one measure of genomic instability. The clinical implication of copy number change in advanced prostate cancer, which defines a wide spectrum of disease fro
Externí odkaz:
https://doaj.org/article/506e0f56118040028d430cc8873797f0
Autor:
Alex Hoyle, Christopher D. Brawley, Adnan Ali, Emily Grist, Louise Brown, Leila Zakka, Nafisah B. Atako, Gerhardt Attard, Malissa Richmond, Sofeya Ishaq, Daniel M. Berney, Larissa Mendes, Nicholas D. James, Christopher Sweeney, Noel W. Clarke, Marina Parry, Sara Santos Vidal, Aine Haran, Sharanpreet Lall, Mahesh K. B. Parmar
Publikováno v:
Journal of Clinical Oncology. 39:5076-5076
5076 Background: Treatment intensification with docetaxel or abiraterone improved survival for advanced prostate cancer starting androgen deprivation therapy (ADT) in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug
Autor:
Alex Hoyle, Marina Parry, Larissa Mendes, Christopher D. Brawley, Leila Zakka, Noel W. Clarke, Nicholas D. James, Louise Brown, Nafisah B. Atako, Sharanpreet Lall, Paolo Cremaschi, Sara Santos Vidal, Mahesh K. B. Parmar, Gerhardt Attard, Adnan Ali, Emily Grist, Malissa Richmond, Sofeya Ishaq, Daniel M. Berney, Stefanie Friedrich
Publikováno v:
Journal of Clinical Oncology. 39:5021-5021
5021 Background: Men with advanced hormone-sensitive prostate cancer (HSPC) starting long term androgen deprivation therapy (ADT) follow a highly variable clinical course. Treatment intensification with docetaxel or AR targeted therapies improves out